

**North Central Cancer Treatment Group**

N057K: Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ)  
Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma

Status Change Notice – January 24, 2012

**NOTICE OF STATUS CHANGE**

This study is reopened to patient accrual effective January 24, 2012 due to the resumption of the delivery of Afinitor<sup>®</sup> (everolimus; RAD001) investigational drug re-supply from the sponsor Novartis.

**Please retain this notice with the protocol.**